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Abstract
Effects of the leaf extract Ginkgo
biloba, ginkgolides A and B, and the
amino acid taurine (2-aminoethane
sulfonic acid) on platelet aggregation was
studied. All potential anitcoagulants were
incubated in day one platelet-rich plasma
and subjected to various agonist-induced
clotting and tests and other measures of
platelet viability. G. biloba extract and its
respective ginkgolides had no effect on
platelet aggregation in response to ADP
and thrombin, while taurine exhibited
prolongation of thrombin time (TT) and
reduced thrombin-induced aggregation
by 10%. Taurine prolonged time of
initial clot formation on thrombolestographic tests, but overall clot
viability remained unaffected. These data
suggest that G. biloba and its active
ginkgolides do not inhibit platelet
aggregation induced by ADP and
thrombin, while taurine mildly inhibits
thrombin-induced platelet aggregation.
These findings correlate with taurine's
osmoregulatory and cryoprotective
properties and indicate a role as a
hemostasis stabilizer rather than an
anticoagulant. Possible mechanism of
taurine action is suggested.
Abbreviations: EGb 761, Ginkgo bi/oba
extract; GA, ginkgolide A; GB, ginkgolide
B; PT, prothrombin time; APTT, activated
partial thromboplastin time; TT, thrombin
time; ESC, extent of shape change; HSR,
hypotonic shock response; PRP, plateletrich plasma; PPP, platelet-poor plasma.

Introduction
Leaves from the plant Ginkgo biloba
have been an integral part of Chinese
herbal medicine for over 5,000 years, but it
is only fairly recently that Western
medicine has acknowledged it's
physiological effects and pharmacological
implications. Similarly, taurine, an amino
acid ubiquitous throughout the animal
kingdom, has an ancient evolutionary
history, but only in recent decades has it
stimulated interest in the biomedical
community. Many biological effects of
G. bi/oba have been reported in current
literature including cerebrovascular and
memory enhancement, 1,2 antioxidant
action,>' 3 neurotransmitter stimulation,>' 3
and inhibition of platelet aggregation. 1-5
Taurine exerts a similarly copious influence
on biological phenomena with effects
including bile conjugation, 68
osmoregulation, 6,8-9 membrane
stabilization, 6,9 cellular calcium
modulation, 6,10 anti oxidation , 6,7 and
inhibition of platelet aggregation. 6, 10-13
G. biloba and taurine's influence on
platelet aggregation is the exclusive focus
of this study.
The number of studies on G. biloba is
rapidly increasing, due in no small part to
the American public's increasing
fascination with complimentary and
alternative medicine and accordingly, the
traditional healer's sensitivity to the needs
of his or her patients. Due to its
classification as a supplement, G. biloba
extract (EGb 761), the commercially
available form of the herb, is not regulated
by the FDA, and because it can be
purchased over-the counter, adverse side
effects and/or drug-interactions are usually
not considered before taking the
supplement. Similarly, physicians may not
realize their patients are using herbal
extracts until a potentially dangerous
situation presents itself, such as in
situations of perioperative care. 3
EGb 761 is purified and concentrated
1:50 (extract: leaves) and consists of 24%
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flavonoid glycosides compounds, 2.4%
bilobalide, and 2, 0.8, and 1% ginkgolides
A, B, and C, respectively (Fig. 1). The
extract is processed as a powder and
manufactured in pill-form by various
pharmaceutical companies.
Figure 1. Chemical structures of Ginkgo biloba
extract (EGb 761) constituents

_.

A.
B.

Glucorhamnoside ester of
kaempferol (R=H) and quercetin
(R=OH): Flavenoid fraction
Ginkglodides and bilobalide:
Terpene lactone fraction
GinkgoJide A: R=OH, R =H, R =H
Ginkgolide B: R=OH, R'=OH,
R"=H
Ginkgolide C R=OH,
R'=OH,
R"=OH

Taurine (Fig. 2) has been drawing the
attention of researchers since it was first
isolated from the bile of the ox that carries
its name (Bos taurus). A quick glance at its
phylogenic distribution and physiological
influence reveals why. Taurine is present in
surprisingly high concentrations in algae
and in the majority of the animal kingdom,
including arthropods. Except for trace
amounts, taurine is not found in the
bacterial and plant kingdoms, mostly due to
the fact that such organisms possess a cell
wall and are less likely in need of the
osmoregulatory protection taurine provides.
Figure 2. Chemical structure of taurine
(2-aminoethane sulfonic acid)
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Taurine is not utilized in protein synthesis
but rather is found as a free ?-amino acid in
plasma and in tissues, with highest
concentrations found in the excitable
tissues of the heart, brain, and retina. 6,8
It is also found in increasingly high
concentrations in platelets. Taurine is
extremely important in mammalian
developmen.t, and dietary deficiencies have
been linked to pathological conditions such
as cardiomyopathy, retinal degeneration,
growth retardation, hypercholesterolemia,
hepatic disorders, and cystic fibrosis.14
Taurine's developmental importance is
reinforced by the fact that since 1984 the
U.S. Department of Agriculture has
sponsored addition of taurine to human
infant formulas. IS Virtually all infant
formula manufacturers worldwide now
add taurine to their products.
Another interesting aspect of taurine's
role in physiological phenomena is its little
explored or understood role in hibernation
and freeze tolerance. Hatchlings of the
painted turtle Chrysemys picta marginata
are the highest vertebrate life known to
tolerate the natural freezing of extracellular
body fluids during winter hibernation.
When exposed to sub-optimal temperatures,
it has been shown that the total amino acid
pool increases 2.25-fold in the liver,
muscle, and blood, with taurine accounting
for 52% of this increase. 16 Elevated levels
of GABA and taurine have been detected
during hibernation-induced hypothermia in
hedgehogs,17 and it has been shown that in
cold acclimation of garter snakes
(Thamnophis sp.), plasma levels of all
amino acids except taurine significantly
decrease, while taurine itself increases in
concentration. 6 Such research has provided
an impetus for studying taurine's role in
cryopreservation, and it has recently been
shown that taurine pretreatment and its
continued presence during islet
cryropreservation impoves post-thawing
viable recovery of islets. 18
Because of the significant increase in
plasma taurine levels exhibited by several
species during hibernation, a period during

which the cardiovascular system becomes
sluggish, resulting in decreased blood flow
and increased risk of intravascular
thrombus formation, taurine's role as a
potential anticoagulant or hemostatic
stabilizer is probable. It has already been
shown that during hibernation in the frog
Ratna tigrina clotting tests indicate
prolongation of several hemostatic factors
including whole blood clotting time, plasma
recalcification time, cephalin time, and
prothrombin time. 19
While differing markedly in chemical
structure and mechanism of action, EGb 761
and taurine both effect similar biological
processes, notably platelet aggregation. The
mechanism of EGb 761 ' s inhibitory action
in the aggregation response has been linked
to the inhibition of Platelet Activation
Factor. It has also been linked to inhibition
of aggregation induced by oxidative stress,
with ginkgolides A and B of the terpene
fraction exerting the greatest inhibitory
effect.l~3 Taurine's inhibition of platelet
aggregation is associated with its effects on
intercellular calcium ion translocation, but a
universally agreed upon mechanism has yet
to be proposed.
While several studies have addressed
G. biloba and taurine's inhibitory effects on
platelet aggregation in vitro, a direct
comparison of both compounds and their
effects on platelet aggregation and other
factors of hemostasis remains to be studied.
EGb 761, ginkgolides A and B, and taurine
were examined in relation to their effects
on aggregation of platelet rich plasma
through agonist-induced lumi-aggregation
and thrombelastography methods with the
goal of contributing to this understanding.

Materials and Methods

Materials
G. biloba leaf extract (standardized to
24% flavonoid glycosides, 2.4% bilobalide,
and 2, 0.8, and 1% ginkgolides A, B, and
C, respectively) was purchased in powdered
pill form from Rite-Aid pharmacy

(Washington, D.C.). Purified ginkolides A
and B, taurine, ADP, thrombin, and all
other reagents were purchased from Sigma
Chemicals (St. Louis, MO).
Platelet supply and cell adjustment
Donor plasma units were obtained
from Walter Reed Army Medical Center
under a protocol approved by the
Institutional Review Board. Plasma (101
mL containing approximately 17 mL ACDA anticoagulant) was frozen at -70°e. At
the time of experiments plasma was rapidly
thawed at 37°C and processed for STA
Compact coagulation assay. For all other
assays, unfrozen, unthawed, day one (postdonation) Platelet Rich Plasma (PRP) was
used. Units were kept under standard blood
banking conditions (22°C with rotation)
until testing. PRP cell count was performed
on an automated cell counter (Cell-Dyne
1700, Abbott Diagnostics Division,
Mountain View, CA) and later adjusted to
300 x 103 cells/uL with HEPES-buffered
platelet-poor plasma (PPP). PPP was
prepared by centrifugation of PRP at 3000
x g for 20 minutes at 22°C. HEPES buffer
(137 mM NaCl, 2.7 mM KCI, 1mM MgCl b
5.6 mM glucose, and 3.8 mM HEPES,
pH7.4) was added to PPP for a final
concentration of .0152 HEPES (%vol.)
Stock Solution Premaration
Powdered G. iloba extract was
partially dissolved in Ix PhosphateBuffered Saline and filtered through a 20
mosmol porosity hypodermic syringe filter
to a final concentration of 1000 mg/mL.
Ginkgolides A and B were partially
dissolved in Ix PBS and placed in an
ultrasound water bath for complete
dissolution to a final concentration of 1000
mg/mL. Taurine was dissolved in Ix PBS
and adjusted to a concentration of 250 mM.
Solution Incubation and sample hreoaration
PRP was incubated 10:1 wit EGb 761
and ginkgolides (final concentration 100
mg/mL), and 10: 1 and 50: 1 with taurine
(25 mM, 5 mM final concentrations,
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respectively) at 37°C for 1 hour. Cell count
of incubated PRP was then adjusted to 300
x 10 3 cells/ul with HEPES-buffered PPP.
Based on initial PRP cell count, EGb 761,
ginkgolides A and B, and taurine stock
solutions were added to HEPES-buffered
PPP before dilution in order to retain their
respective concentrations in solution.
Clotting Time
Platelet samples were stimulated with
various agonist-induced clotting tests and
other measures of platelet viability. In vitro
testing of coagulation was measured using
the SPA Compact electromechanical clot
detection system (Chronolog, Havertown,
PA). All assays were carried out according
to standard procedures developed by
American Bioproducts. The following
measures of the extrinsic clotting cascade
were measured: Prothrombin Time (PT)a mixture of thromboplastin with calcium is
added to citrated plasma, Activated Partial
Thromboplastin Time-involves the
recalcification time of plasma in the
presence of a standardized amount of
cephalin and activator silica, and Thrombin
Time (TT)-in the presence of 0.5 u/ml
thrombin, plasma will consistently clot in a
finite time unless there is insufficient or
abnormal fibrin formation. Taurine was
prepared in 5 and 25 mM concentrations
in plasma.
Extent of Platelet Shape Change induced by
ADP and Hypotonic Shock Response
Extent of ADP-induced platelet Shape
Change (ESC) and osmotic Hypotonic
Shock Response (HSR) was measured as
the change in optical density of the reaction
mixture using the SPA-2000 instrument
(Chronolog, Havertown, PA). The sample
contained EDTA (2 mM final
concentration) to prevent aggregation. ADP
(0.02 mM final concentration) induces
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platelet shape change from discoid to
spherical shape with pseudepodial
projections, causing an increase in optical
density. The difference is computed
automatically and given as a percentage.
Duplicate measurements were compiled
from five donors.
Platelet aggregation by thrombin
1.0 u/mL thrombin-induced
aggregation was performed and monitored
with a luminescent aggregometer
(Chronolog, Havertown, PA), also utilizing
change in optical density as an indication of
platelet response. Aggregation results were
measured as a percentage of maximum
light transmittance as determined by PPP.
Using AGGRP/LINK software, the slope
(S) and amplitude (A) of the generated
curves were computed. Duplicate
measurements were compiled from
five donors.
Thrombelastography
To gain a better understanding of the
additive's effects on hemostasis as a whole,
thrombelastograpy (TEG), which measures
the kinetic changes associated with clotting
and clot retraction, was performed on the
TEG Coagulation Analyzer 5000
(Haemoscope, Skokie, IL). A normal
thrombelastographic tracing with associated
values is represented in Fig. 3. Disposable
cups and pins were used in accordance with
manufacturer guidelines. Coagulation was
induced by thrombin (0.6 U/mL final
concentration) and CaCl 2 (6.25 mM final
concentration) While thrombelstagraphic
tracings evaluate many aspects of platelet
response, Maximum Amplitude (MA)
and R time were focused on in this
experiment. Duplicate runs were
compiled from five donors.

Figure 3. Diagrammatic thrombelastographic
tracing 20
Width of the tracing in
millimeters is proportional
to the elastic sheer
modulus produced when
the sample clots. Five
standard measurements
can be extrapolated from
the tracing:
R value distance
from addition of agonist
to initial clot formation
K value- distance
from 1 mm to 20 mm
wide curve
_- angle (in degrees)
from the enter line of
the curve to a line
running from 1mm point
tangential to the curve
Maximum Amplitude
(MA)-maximum width
of the curve
A 6o - width of curve at
60 minutes (or 60
minutes after MA)

Figure 4. Effects of Ginkgo biloba and ginkgolides A
and B on ADP-induced Extent of Shape Change
and Hypotonic Shock

Extent of Shape Change (ESC)I
Hypotonic Shock Response

(HSR)
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Figure 5. Effect of ginkolide B on thrombininduced lumi-aggregation.

Stastical Analysis
Mean values ±SE are shown
throughout this report. Statistical
significance of differences between means
was calculated using a paired t test analysis
(MINITAB software, Minitab Inc., State
College, PA). P values are expressed at the
95% confidence level (P>0.05)

Results
Effect of EGb 761 and Ginkgolides A and B
EGb 761 and ginkgolides A and B
exhibited no significant effect on ADPinduced shape change, and little to no effect
on hypotonic shock response of platelet
samples (Fig. 4). Similarly, EGb 761 and its
respective ginkgolides had no observable
effect on lumi-aggregation (Fig. 5).
Ginkgolide B, the most potent inhibitor of
aggregation response based on current
literature, is shown as indicative of this null
response. No significant effect was
observed on thrombelastography and
plasma clotting times.

Taurine
Taurine also had no significant effect
on ADP-induced shape change (Fig. 6).
ESC for control platelets was 30.02% ±
6.81, while ESC for platelets incubated
with 5 and 25 mM taurine was 28.85% ±
4.64 and 33.57 ± 4.9, respectively. Both
values were not statically different from
the control.
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Figure 6. Effect of taurine on ADP-induced Extent
of Shape Chan2e.

Control

5mM Taurine

B.

25mM Taurine

Taurine exhibited significant inhibition
of platelet aggregation in lumi-aggregation
(Fig. 7). Aggregation of control platelets is
characterized by A = 94% and S = 119.25
mM taurine displayed notable decrease in
amplitude, with A = 81 % and S = 114. 5
mM taurine displayed a similar 10%
reduction in aggregation response,
indicating a saturating effect and a lack of
dose-dependence inhibition in
concentrations greater than 5 mM.

While taurine produced an increase in
time of initial clot formation (R), overall
clot viability (MA) was unaffected. Control
MA = 73.95 ± 2.30 mm, while 25 mM
taurine produced a stastically insignificant
decrease with an MA = 72.60 ± 2.60 mm.
This effect is observable in figure 8.

Figure 8. Thrombelastographic effects of 25 mM
taurine on thrombin-induced aggregation.

Figure 7. Effects of taurine on thrombin-induced
Inmi-aggregation: A. Effect of taurine
concentration on inhibition response.
B. Representative 25 mM taurine tracing
exhibiting aggregation inhibition.

Results of plasma clotting tests are
presented in figure 9. A significant increase
of TT was observed at 25 mM
concentration, prolonging TT by 9%. While
this observation is stastically significant,
(P<0.05), it is not clinically significant, as
the data obtained still falls in the normal TT
range. PT and APTT remained unaffected
by taurine.
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Figure 9. Effect of taurine on plasma clotting time.

c::J Control
_

25mM Taurine

J

Discussion
Although several studies have
demonstrated inhibition of platelet
aggregation by G. biloba and taurine, none
have used thrombelastography as a
comparative hemostatic measurement. The
results obtained support those present in the
literature, as EGb 761 and ginkgolides A
and B had no effect on ADP or thrombininduced aggregation. These findings support
the specificity of G. biloba's anticoagulant
action, which purportedly acts by inhibiting
Platelet Activating Factor and coagulation
induced by oxidative-stress. The slight
decrease in HSR produced by EGb 761 is
more an indication of faulty reagent
preparation than osmoregulatory action. As
the only readily obtainable form of EGb 761
was the pill form, cellulose and other
pharmaceutical additives prevented
dissolution in PBS, and filtration was
necessary to prevent hyperosmotic
conditions that might have effected
aggregation studies. The filtration procedure
was obviously not successful, and future
studies would warrant obtaining EGb 761 in
hydrophilic liquid form to prevent such
sources of error. Ginkgolides A and B,
which did dissolve in PBS after ultrasound
treatment, did not show any significant
change in osmoregulatory response.
While Taurine also exhibited a null
effect on ADP-induced shape change
(Fig.6), it did inhibit thrombin-induced
lumi-aggregation by 10% (Fig. 7).

Increasing concentration from 5 to 25 mM
did not contribute to further augmentation
of the inhibitory effect. It has been assumed
that taurine's inhibitory action on platelet
aggregation can be attributed to its
regulation of intracellular Ca2+ movement.
It has been postulated that platelet shape
change is mediated by both calcium
dependent and independent pathways.21
When agonist-induced cytosolic Ca2+
increases were prevented by a cytosolic
Ca2+ chelator, platelets still underwent shape
change. Thus it is possible that in the
presence of taurine ESC remains
unchanged as calcium independent
pathways compensate for its inhibitory
action on intracellular translocation.
Thrombelastographic analysis revealed
a significant decrease in R value distance,
which is associated with initial clot
formation, while MA value remained
unaffected. This indicates an initial
inhibition of platelet response being
eventually counteracted by other plasma
coagulation elements. MA represents the
maximum clot elastic shear modulus of the
developed clot, and is an indication of the
interaction between platelets and fibrin
strands. Initial clot formation was mildly
inhibited while overall clot viability
remained unaffected. As MA represents an
integral function of several hemostatic
elements, the 10% reduction in thrombininduced platelet aggregation observed in
lumi-aggregation tests is not enough to
significantly impact the overall strength of
the clot.
Taurine was found to have a marginal
effect on TT, while leaving PT and APTT
unaffected (Figure 9). The minor effect on
TT is not clinically significant, as TT
remained within the normal range. Due to
the lack of a significant impact on the
clotting tests taurine cannot be considered
an anticoagulant. However, due to its
statistically significant effect on TT it may
be pictured as a TT regulator during
conditions of hypothermia when its
concentration in plasma profoundly
increases. Interestingly, Ahmad et al. report
Osprey Journal of Ideas and Inquiry 7

prolongation of several clotting tests but no
change in TT during hibernation in frogs,
indicating that there is no significant
decrease in the plasma fibrinogen level. 19
Boral et al. even reported an increased
plasma fibrinogen level of blood in the
hibernating toad. 21
It can be inferred from these results
and the results obtained that taurine
regulates IT by modifying the sensitivity of
the Ca2+ binding site of fibrinogen to Ca2+.
Ca2+ ions are known to accelerate
polymerization of fibrin monomers, and it
has been recently shown that the function
of the polymerization site depends on the
structural integrity of its nearby Ca2+ site. 23
It is suggested that taurine acts by
modifying the sensitivity of the Ca2+
binding site of fibrinogen to Ca2+, thus
indirectly impairing polymerization. The
result is a slight prolongation of TT that
may be of a special importance under
hypothermic conditions or conditions of
elevated fibrinogen levels.
It is not clear yet what mechanisms are
at work in hibernating animals that are able
to sustain sluggish blood flow without risk
of microvascular blockade, however this
research supports taurine as a probable
hemostatic stabilizer rather than an
anticoagulant. Increased levels of taurine in
plasma during hibernation can be attributed
to an increased requirement for hemostasis
regulation and prevention of hypercogulative states by modifying the Ca2+
binding site of fibrinogen and thus
regulating polymerization during
hyperthermic conditions.
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